SCHEMBL6000985

SCHEMBL6000985

CCCC(CCC)c1ccc(OCc2ccc(-c3csc(CN(CC(=O)O)CC(=O)Nc4ccccc4)n3)cc2)cc1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTPN2 P17706 1/20 0.69
PTPN1 P18031 1/20 0.69
MMP13 P45452 7/20 0.44
MMP2 P08253 4/20 0.44
MMP1 P03956 2/20 0.44
MMP9 P14780 2/20 0.44
FNTA P49354 2/20 0.41
FNTB P49356 2/20 0.41
FFAR1 O14842 1/20 0.40
ALDH1A1 P00352 2/20 0.40
MAPT P10636 1/20 0.40
ALOX5 P09917 2/20 0.39
PPARD Q03181 1/20 0.39
PPARA Q07869 1/20 0.39
LTA4H P09960 2/20 0.38
RAB9A P51151 2/20 0.38
MEN1 O00255 1/20 0.38
NPC1 O15118 1/20 0.38
KMT2A Q03164 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6000992 0.94 PTPN2 (0.68) PTPN2PTPN1MMP13MMP2MMP1
SCHEMBL6000494 0.93 PTPN2 (0.66) PTPN2PTPN1MMP13MMP2MMP1
SCHEMBL6000764 0.93 PTPN2 (0.66) PTPN2PTPN1MMP13MMP2MMP1
SCHEMBL6000626 0.91 PTPN2 (0.66) PTPN2PTPN1MMP13MMP2MMP1
SCHEMBL6000765 0.90 PTPN2 (0.64) PTPN2PTPN1MMP13MMP2MMP1
SCHEMBL6001057 0.90 PTPN2 (0.64) PTPN2PTPN1MMP13MMP2MMP1
SCHEMBL6001017 0.90 PTPN2 (0.76) PTPN2PTPN1MMP13MMP2MMP1
SCHEMBL5999110 0.90 PTPN2 (0.76) PTPN2PTPN1MMP13MMP2MMP1
SCHEMBL6000495 0.89 PTPN2 (0.56) PTPN2PTPN1MMP13MMP2MMP1
SCHEMBL6000546 0.88 PTPN2 (0.55) PTPN2PTPN1ALDH1A1MAPTRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060122181-A1 Heteroaromatic pentacyclic compound and medicinal use thereof JAPAN TOBACCO INC. (JP) 2006-06-08 US claimed
EP-1553091-A1 HETEROAROMATIC PENTACYCLIC COMPOUND AND MEDICINAL USE THEREOF JAPAN TOBACCO INC. (JP) 2005-07-13 EP claimed
US-20060122181-A1 Heteroaromatic pentacyclic compound and medicinal use thereof JAPAN TOBACCO INC. (JP) 2006-06-08 US disclosed
EP-1553091-A1 HETEROAROMATIC PENTACYCLIC COMPOUND AND MEDICINAL USE THEREOF JAPAN TOBACCO INC. (JP) 2005-07-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060122181-A1 Heteroaromatic pentacyclic compound and medicinal use thereof PTPN11, PTPN1, PTPN3 PTPN2 11/4885PTPN1 2/4885MMP13 2340/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.